Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $285.19 USD
Change Today -10.22 / -3.46%
Volume 4.0M
ACT On Other Exchanges
New York
As of 8:04 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $317.72
52 Week Low
05/9/14 - $193.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Details

Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women’s health, oncology, and other therapeutic categories. In addition, it offers pharmaceutical products in the areas of urology, gastroenterology, and dermatology therapeutic categories. The company produces medicines in various formulations, including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids, and semi-solids. It sells its products in Ireland and internationally. Actavis plc was founded in 1983 and is based in Little Island, Ireland. The company has development and manufacturing facilities in Europe, the United States, and Asia.

21,600 Employees
Last Reported Date: 02/18/15
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $2.6M
Chief Operating Officer
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® in the Treatment of ABSSSI

Actavis plc announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1,500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). Preliminary top-line data demonstrated the 1,500 mg single-dose of DALVANCE achieved its primary endpoint of non-inferiority to the two-dose regimen (10% non-inferiority margin) at 48-72 hours after initiation of therapy, as determined by a decrease of > 20% in lesion area relative to the baseline measurement (81.4% vs. 84.2 % for the single dose vs. the two dose regimen, respectively; Difference -2.9; 95% CI: -8.5, 2.8) Similar proportions of patients with Staphylococcus aureus infections at baseline were clinical responders at the 48-72 hour time-point within each treatment group (122/137 (89.1%) in the single-dose treatment group and 124/145 (85.5%) in the two-dose treatment group). In addition, the trial assessed the secondary outcome measures of clinical response at Day 14 (the EMA Primary Endpoint) as well as at Day 28. The single-dose of DALVANCE provided similar treatment efficacy to the two dose regimen in these secondary endpoints. 94.4% of patients in the single-dose DALVANCE arm and 94.0% of patients in the two-dose DALVANCE arm achieved clinical success at Day 14 (95% CI -3.5, 4.3). At Day 28, 84.5% of patients treated with a single-dose of DALVANCE achieved clinical success compared to 85.1% of those treated with the two-dose regimen of DALVANCE (95% CI -6.0, 4.8). Actavis plans to file a supplemental New Drug Application (sNDA) with these data in third quarter of 2015.

Cipher Pharmaceuticals Announces Outcome of Markman Hearing Related to Watson's Abbreviated New Drug Application for a Generic Version of Absorica

Cipher Pharmaceuticals Inc. announced that the Court has issued an opinion in the claim construction hearing for the patent infringement suit by Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc., Galephar Pharmaceutical Research Inc., and Cipher against Watson Laboratories Inc. related to Watson's Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules). The purpose of a Markman hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit. No ultimate determination of infringement or validity of the patents has been determined at this point.

Actavis plc Launches AVYCAZ (Ceftazidime-Avibactam) Anti-Infective in United States

Actavis plc announced AVYCAZ™ (ceftazidime-avibactam) is now available for ordering by hospitals across the United States. AVYCAZ is indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. As only limited clinical safety and efficacy data for AVYCAZ are currently available, AVYCAZ should be reserved for use in patients who have limited or no alternative treatment options. AVYCAZ combines ceftazidime, a cephalosporin with in vitro activity against certain Gram-negative and Gram-positive bacteria, and avibactam, a non-beta-lactam beta-lactamase inhibitor that inactivates certain key beta-lactamases and protects ceftazidime from degradation by these beta-lactamases. The addition of avibactam to ceftazidime protects ceftazidime from breakdown by Extended Spectrum Beta-Lactamases (ESBL), Klebsiella pneumoniae carbapenemase (KPC) and AmpC producing pathogens. AVYCAZ is part of Actavis' portfolio of infectious disease products that address some of the most dangerous pathogens. AVYCAZ received a priority review and FDA approval was supported in part by the FDA's previous findings of efficacy and safety of ceftazidime for the treatment of cIAI and cUTI. In addition, the contribution of avibactam to AVYCAZ was primarily established via in vitro data and animal models of infection. AVYCAZ was studied in two Phase II, randomized, blinded, active controlled, multicenter trials, one each in cIAI and cUTI, including pyelonephritis. These studies were not designed with any formal hypotheses for inferential testing against the active comparators. AVYCAZ for injection is supplied in single-use, clear glass vials for reconstitution. It is available to hospitals for purchase in cartons of ten (10) 2.5 g vials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $285.19 USD -10.22

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,706 GBp -44.00
Bristol-Myers Squibb Co $65.16 USD -0.64
GlaxoSmithKline PLC 1,562 GBp +27.50
Medtronic PLC $76.21 USD -1.40
Novo Nordisk A/S kr394.00 DKK +3.70
View Industry Companies

Industry Analysis


Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 2.8x
Price/Cash Flow 123.7x
TEV/Sales 7.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at